Thromboembolism Concern with Hormonal Contraceptive Use

Meghan Smith, Ariana Covino, Olivia Nash, Hannah LeClair

University of Maine School of Nursing

NUR 456: Professional Practice through the Lifespan

Dr. Valerie Herbert

February 17, 2023

Abstract

When addressing risk of thromboembolism in women prescribed hormonal contraception, an evidenced-based PICO question was explored: In women of childbearing age prescribed hormonal contraceptives, how does physician medication management of contraceptives affect hospitalization rates of women suffering from thromboembolism complications due to the side effects of birth control compared to women who don't receive medication management from physicians? The literature indicates women have an increased risk of thromboembolism, especially in conjunction with comorbidities. Women's health is an aspect of healthcare that has an increased need for attention and care, and it is vital they have adequate healthcare checkups to address specific women's health issues and care (Geampana, 2019). This risk can be assessed through specific management on contraceptive use, supporting patients in accessing gynecological healthcare, improvement on taking an adequate menstrual history and assessing for sequelae of heavy menstrual bleeding (Gray et al., 2018). To shine light on the high risk of thromboembolism while using hormonal contraceptives, a search was conducted for research articles within the CINAHL database using the keywords thromboembolism, hormonal contraceptive, women and management. Search criteria required all articles to have been published between 2017 and 2023. Any articles before 2017 and without the key words listed were excluded, resulting in ten peer-reviewed articles. Research highlights several recommendations for women on hormonal contraceptives in order to reduce the hospitalizations rates of women due to side effects of hormonal contraceptives, including: (a) regular assessments, (b) detailed medical history, (c) analysis of risks, and (d) and regular follow-up appointments.

Key Words: thromboembolism, hormonal contraceptive, women, management

References

- Geampana, A., (2019). One blood clot is one too many: Affected vocal users' negative perspectives on controversial oral contraceptives. *Qualitative Health Research*, 29(10): 1383–1394. 10.1177/1049732319839027
- Gray, B., Floyd, S., & James, A. (2018). Contraceptive management for women who are at high risk of thrombosis. *Clinical Obstetrics & Gynecology*, 61(2), 243–249. https://doi.org/10.1097/grf.000000000000356
- Heikinheimo, O., Toffol, E., Partonen, T., But, A., Latvala, A., & Haukka, J. (2022). Systemic hormonal contraception and risk of venous thromboembolism. *Acta Obstetricia Et Gynecologica Scandinavica*, 101(8), 846–855. <u>https://doi.org/10.1111/aogs.14384</u>
- Hormonal birth control & blood clot risks (2022). *National Women's Health Network*. <u>https://nwhn.org/hormonal-birth-control-blood-clot-risk/</u>
- Jacobson, J., Nasso, J., & Glantz, J. (2018). Use of an evidence-based guideline for management of side effects from long-acting reversible contraceptives: A quality improvement report. *Journal of Midwifery & Women's Health*, 64(2), 225–229.

https://doi.org/10.1111/jmwh.12925

- Keenan, L., Kerr, T., Duane, M., & Van Gundy, K. (2018). Systematic review of hormonal contraception and risk of venous thrombosis. *The Linacre quarterly*, 85(4), 470–477. <u>https://doi.org/10.1177/0024363918816683</u>
- Klok, F. A., & Barco, S. (2019). Optimal management of hormonal contraceptives after an episode of venous thromboembolism. *Thrombosis Research*, 181, S1-S5. <u>https://doi.org/10.1016/s0049-3848(19)30357-3</u>

Kurvits, K., Laius, O., Uusküla, M., & Laanpere, M. (2021). Trends in the use of hormonal contraception in Estonia 2005–2019 and the risk of arterial and venous thromboembolism: A population-based study. *The European Journal of Contraception & Reproductive Health Care*, 26(5), 413–420.

https://doi.org/10.1080/13625187.2021.1931839

- Maher, K., Quint, E., Weyand A. (2022). Management of contraception in adolescent females with hormone-related venous thromboembolism. *Journal of Adolescent Health*, 71(1). <u>https://doi.org/10.1016/j.jadohealth.2022.02.009</u>
- Römer, T., (2019). Medical eligibility for contraception in women at increased risk. *Deutsches* Ärzteblatt International, 116(45), 764-774. <u>10.3238/arztebl.2019.0764</u>
- Tepper, N. K., Godfrey, E. M., Folger, S. G., Whiteman, M. K., Marchbanks, P. A., & Curtis, K. M. (2018). Hormonal contraceptive use among women of older reproductive age:
 Considering risks and benefits. *Journal of Women's Health*, 27(4), 413–417.
 https://doi.org/10.1089/jwh.2018.6985